Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS15
PHASE 3 / 2-36
RECRUITING3
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO0%
Delay Index: of 6 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| FCN-159 NCT05997602 |
P2 | Recruiting | Langerhans Cell Histiocytosis; LCH | 56 | 2025-05-14 |
| Drug: Foritinib Succinate NCT06569420 |
P3 | Active, not recruiting | Non-Small Cell Lung Cancer; ALK-positive | 275 | 2025-07-31 |
| Test group (Group A): FCN-159 8 mg, orally, once daily; NCT05913037 |
P3 | Active, not recruiting | Neurofibromatosis 1; Plexiform Neurofibroma | 167 | 2025-08-19 (+2 mo) |
| FCN-338 + Azacitidine NCT06858618 |
P2 | Active, not recruiting | Safety; Antitumor Activity | 47 | 2026-12-01 |
| XH-S004 20 mg NCT06981091 |
P2 | Active, not recruiting | Non-Cystic Fibrosis Bronchiectasis | 234 | 2027-01-08 |
| FXS5626 tablet NCT07552012 |
P2 | Recruiting | Active Non-anterior, Non-infectious Uveitis | 40 | 2027-02-28 |
| Luvometinib NCT07004075 |
P3 | Not yet recruiting | Low-grade Glioma; Pediatric Low-grade Gliomas | 102 | 2027-04-30 |
| FXS6837 Dose 1 NCT07502638 |
P2 | Not yet recruiting | IgAN | 60 | 2027-09-12 |
| Intervention1: FXS5626 Tablets NCT07840820 |
P2/3 | Not yet recruiting | Non-segmental Vitiligo | 480 | 2027-11-10 |
| XS-03-II201 NCT06936527 |
P1/2 | Enrolling by invitation | Colorectal Cancer; Metastatic Colorectal Cancer With RAS Mutation | 102 | 2028-04-30 |
| FXS6837 Capsule NCT07747090 |
P3 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 90 | 2028-05-05 |
| FXS6837 Capsule NCT07914894 |
P3 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 20 | 2028-05-17 |
| luvometinib + anlotinib NCT07562581 |
P2 | Recruiting | Non-small Cell Lung Caner; KRAS-mutated | 48 | 2029-06 |
| Luvometinib Tablets NCT07024394 |
P1/2 | Not yet recruiting | Neurofibromatosis 1; Plexiform Neurofibroma | 65 | 2029-09-23 |
| FXS6837 Capsule NCT07750665 |
P2 | Not yet recruiting | Primary IgAN | 60 | 2029-11-13 |